-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown pandemic has brought major challenges to the current global health system, but so far there is still no specific drug for the new crown virus ( COVID-19 )
.
Although it is not recommended to treat patients with viral infections with antibiotics , antibiotics are common in certain countries, especially in the early stages of COVID-19 patients
The new crown pandemic has brought major challenges to the current global health system, but so far there is still no specific drug for the new crown virus ( COVID-19 )
This study is a multi-center retrospective cohort study that included a total of 1,373 non-severe COVID-19 hospitalized patients who were admitted to the hospital without bacterial infection
.
According to the patient's exposure to antibiotics within 48 hours after admission, the patients were divided into two groups, the antibiotic treatment group and the non-antibiotic treatment group
During the 30-day follow-up, the proportion of patients in the early antibiotic use group who progressed to severe COVID-19 was almost 1.
4 times that of the control group
.
In the mixed-effects model, early use of antibiotics is associated with a higher likelihood of developing severe illness and hospitalization for more than 15 days
This study found that the early use of antibiotics in non-severe COVID-19 patients is significantly related to the risk of progression from non-severe to severe and the length of hospital stay
.
The researchers also found that the use of azithromycin was not associated with better clinical outcomes
This study found that the early use of antibiotics in non-severe COVID-19 patients is significantly related to the risk of progression from non-severe to severe and the length of hospital stay
Original source:
XiaoxvYin.
Evaluation of early antibiotic use in non-severe COVID-19 patients without bacterial infection: Early antibiotic use in non-severe COVID-19.
Leave a message here
